- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05169567
Abemaciclib (LY2835219) plus fulvestrant vergeleken met placebo plus fulvestrant bij eerder behandelde borstkanker (postMONARCH)
postMONARCH: een gerandomiseerde, dubbelblinde, placebogecontroleerde, fase 3-studie om de werkzaamheid van Abemaciclib Plus Fulvestrant te vergelijken met Placebo Plus Fulvestrant bij deelnemers met HR+, HER2-, gevorderde of gemetastaseerde borstkanker na progressie op een CDK4 & 6-remmer en endocriene Behandeling
This study will evaluate the effect of adding abemaciclib to fulvestrant for the treatment of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer that progressed or recurred after previous treatment with a type of drug known as a CDK4/6 inhibitor and endocrine therapy. Participation could last up to 5 years, depending on how you and your tumor respond.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Fase 3
Uitgebreide toegang
Contacten en locaties
Studie Locaties
-
-
-
San Juan, Argentinië, 5400
- CER San Juan
-
-
Buenos Air
-
Buenos Aires, Buenos Air, Argentinië, C1426ABP
- Fundación Respirar
-
Ciudad Autónoma de Buenos Aire, Buenos Air, Argentinië, C1027AAP
- Centro de Investigaciones Metabólicas (CINME)
-
-
Buenos Aires F.D.
-
CABA, Buenos Aires F.D., Argentinië, 1125
- Fundación Cenit Para La Investigación En Neurociencias
-
-
Córdoba Province
-
Río Cuarto, Córdoba Province, Argentinië, 5800
- Instituto Médico Río Cuarto
-
-
Tucumán Province
-
San Miguel de Tucumán, Tucumán Province, Argentinië, 4000
- Centro Medico San Roque
-
-
-
-
-
Namur, België, 5000
- CHU UCL Namur/Site Sainte Elisabeth
-
-
Antwerpen
-
Brasschaat, Antwerpen, België, 2930
- Algemeen Ziekenhuis klina
-
-
Limburg
-
Hasselt, Limburg, België, 3500
- Jessa Ziekenhuis
-
-
-
-
Capital Region
-
Copenhagen, Capital Region, Denemarken, 2730
- Herlev and Gentofte Hospital
-
-
Central Jutland
-
Herning, Central Jutland, Denemarken, 7400
- Regionshospitalet Gødstrup
-
-
-
-
Aquitaine
-
Bordeaux, Aquitaine, Frankrijk, 33076
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
-
-
Finistère
-
Brest, Finistère, Frankrijk, 29609
- CHRU de Brest
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Frankrijk, 44277
- Hôpital privé du Confluent SAS
-
-
Vendée
-
La Roche-sur-Yon, Vendée, Frankrijk, 85000
- CHD Vendee
-
-
-
-
-
Thessaloniki, Griekenland, 546 45
- Euromedica General Clinic of Thessaloniki
-
-
Achaḯa
-
Pátrai, Achaḯa, Griekenland, 26504
- University Hospital of Patras
-
-
Attikí
-
Athens, Attikí, Griekenland, 115 28
- Alexandra Hospital
-
-
Irakleío
-
Heraklion, Irakleío, Griekenland, 711 10
- University General Hospital of Heraklion
-
-
-
-
-
Budapest, Hongarije, 1122
- Országos Onkológiai Intézet
-
Budapest, Hongarije, 1062
- Magyar Honvedseg Egeszsegugyi Kozpont
-
-
Bács-Kiskun county
-
Kecskemét, Bács-Kiskun county, Hongarije, 6000
- Bacs-Kiskun Megyei Korhaz
-
-
Győr-Moson-Sopron
-
Győr, Győr-Moson-Sopron, Hongarije, 9024
- Petz Aladar Egyetemi Oktato Korhaz
-
-
-
-
Central District
-
Kfar Saba, Central District, Israël, 4428164
- Meir Medical Center
-
Petah Tikva, Central District, Israël
- Rabin Medical Center
-
Ramat Gan, Central District, Israël, 5265601
- Sheba Medical Center
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israël, 9112001
- Hadassah Medical Center
-
-
Southern District
-
Beersheba, Southern District, Israël, 8400000
- Soroka Medical Center
-
-
Tell Abīb
-
Tel Aviv, Tell Abīb, Israël, 6423906
- Sourasky Medical Center
-
-
-
-
-
Bari, Italië, 70124
- Instituto Tumori Giovanni Paolo II
-
Grosseto, Italië, 58100
- Ospedale Misericordia di Grosseto
-
Milan, Italië, 20132
- Ospedale San Raffaele
-
Viterbo, Italië, 01100
- ASL Viterbo Ospedale Belcolle
-
-
Catania
-
Misterbianco, Catania, Italië, 95045
- Humanitas Istituto Clinico Catanese
-
-
Emilia-Romagna
-
Meldola, Emilia-Romagna, Italië, 47014
- IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"
-
-
Friuli Venezia Giulia
-
Udine, Friuli Venezia Giulia, Italië, 33100
- P.O. "S. Maria della Misericordia" Azienda Sanitaria Universitaria Friuli Centrale
-
-
-
-
Estado de Baja California
-
Mexicali, Estado de Baja California, Mexico, 21200
- Centro de Investigacion en Artritis y Osteoporosis SC
-
Tijuana, Estado de Baja California, Mexico, 22010
- COI Tijuana - Centro Oncológico Internacional
-
-
Jalisco
-
Guadalajara, Jalisco, Mexico, 45647
- Centro Oncológico Internacional (COI)
-
-
Nuevo León
-
Monterrey, Nuevo León, Mexico, 64060
- Centro Regiomontano de Investigación
-
-
San Luis Potosí
-
San Luis Potosí City, San Luis Potosí, Mexico, 78209
- Oncologico Potosino, S.C.
-
-
-
-
Masovian Voivodeship
-
Otwock, Masovian Voivodeship, Polen, 05-400
- Europejskie Centrum Zdrowia - Oddzial Onkologii
-
-
Opole Voivodeship
-
Opole, Opole Voivodeship, Polen, 45-060
- Opolskie Centrum Onkologii w Opolu im. prof. Tadeusza Koszarowskiego
-
-
-
-
-
Badajoz, Spanje, 06006
- Hospital Infanta Cristina
-
Madrid, Spanje, 28009
- Hospital General Universitario Gregorio Marañon
-
Toledo, Spanje, 45007
- Hospital Universitario de Toledo
-
-
A Coruña [La Coruña]
-
A Coruña, A Coruña [La Coruña], Spanje, 15006
- CHUAC-Hospital Teresa Herrera
-
-
Balears [Baleares]
-
Palma, Balears [Baleares], Spanje, 07120
- Hospital Universitari Son Espases
-
-
Barcelona [Barcelona]
-
Barcelona, Barcelona [Barcelona], Spanje, 08003
- Parc de Salut Mar - Hospital del Mar
-
-
Catalunya [Cataluña]
-
Barcelona, Catalunya [Cataluña], Spanje, 08036
- Hospital Clínic de Barcelona
-
-
Murcia, Región de
-
El Palmar, Murcia, Región de, Spanje, 30120
- Hospital Clínico Universitario Virgen de la Arrixaca
-
-
Málaga
-
Málaga, Málaga, Spanje, 29011
- H.R.U Málaga - Hospital Materno-infantil
-
-
Navarre
-
Pamplona, Navarre, Spanje, 31009
- Complejo Hospitalario de Navarra
-
-
Tarragona [Tarragona]
-
Reus, Tarragona [Tarragona], Spanje, 43204
- Hospital Universitari Sant Joan de Reus
-
-
Valenciana, Comunitat
-
Valencia, Valenciana, Comunitat, Spanje, 46017
- Hospital Universitario Doctor Peset
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Kaohsiung Medical University Hospital
-
New Taipei City, Taiwan, 231
- Taipei Tzu Chi General Hospital
-
Taipei, Taiwan, 11217
- Taipei Veterans General Hospital
-
Taipei, Taiwan, 10449
- Mackay Memorial Hospital
-
Taoyuan, Taiwan, 333
- Chang Gung Medical Foundation-Linkou Branch
-
-
Tainan
-
Tainan, Tainan, Taiwan, 71004
- Chi Mei Medical Center
-
-
-
-
-
Hradec Králové, Tsjechië, 500 05
- Fakultni nemocnice Hradec Kralove
-
-
Pardubice Region
-
Pardubice, Pardubice Region, Tsjechië, 53203
- Multiscan
-
-
-
-
-
Adana, Turkije (Türkiye), 01370
- Adana City Hospital
-
Ankara, Turkije (Türkiye), 06520
- Memorial Ankara Hastanesi
-
Ankara, Turkije (Türkiye), 06010
- Ankara Gülhane Eitim ve Aratrma Hastanesi
-
Diyarbakır, Turkije (Türkiye), 21200
- Dicle Üniversitesi
-
Edirne, Turkije (Türkiye), 22030
- Trakya University
-
Istanbul, Turkije (Türkiye), 34722
- TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
-
Malatya, Turkije (Türkiye), 44280
- İnönü Üniversitesi Turgut Özal Tıp Merkezi Eğitim ve Araştırma Hastanesi
-
-
Konya
-
Meram, Konya, Turkije (Türkiye), 42080
- Necmettin Erbakan Meram Medical Fac.
-
-
İzmir
-
Cordaleo, İzmir, Turkije (Türkiye), 009035575
- Izmir Medical Park Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, Verenigde Staten, 85004
- St. Joseph's Hospital and Medical Center
-
-
Arkansas
-
Springdale, Arkansas, Verenigde Staten, 72762
- Highlands Oncology Group
-
-
California
-
Fullerton, California, Verenigde Staten, 92835
- Providence Medical Foundation
-
Los Alamitos, California, Verenigde Staten, 90720
- Cancer and Blood Specialty Clinic
-
Los Angeles, California, Verenigde Staten, 90033
- Keck School of Medicine of USC
-
Los Angeles, California, Verenigde Staten, 90024
- TRIO-US (Translational Research in Oncology-US)
-
Santa Monica, California, Verenigde Staten, 90404
- UCLA Hematology/Oncology - Parkside
-
Sylmar, California, Verenigde Staten, 91342
- Olive View-UCLA Medical Center
-
Torrance, California, Verenigde Staten, 90505
- Torrance Memorial Physician Network / Cancer Care
-
Whittier, California, Verenigde Staten, 90602
- PIH Health Hematology Medical Oncology
-
-
Colorado
-
Denver, Colorado, Verenigde Staten, 80220
- Rocky Mountain Cancer Center - Hale Parkway
-
-
Florida
-
Fort Myers, Florida, Verenigde Staten, 33901-8101
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
Hollywood, Florida, Verenigde Staten, 33024
- Millennium Oncology Research Clinic
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Hospital and Clinics, Sylvester Cancer Center
-
Pensacola, Florida, Verenigde Staten, 32503
- Woodlands Medical Specialists, PA
-
Sarasota, Florida, Verenigde Staten, 34232
- Florida Cancer Specialists SOUTH/Sarah Cannon Research Institute/SCRI
-
West Palm Beach, Florida, Verenigde Staten, 33401
- Florida Cancer Specialists EAST/Sarah Cannon Research Institute/SCRI
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Winship Cancer Institute, Emory University
-
Gainesville, Georgia, Verenigde Staten, 30501
- Northeast Georgia Medical Center
-
Macon, Georgia, Verenigde Staten, 31201
- Central Georgia Cancer Care
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Illinois
-
Harvey, Illinois, Verenigde Staten, 60426
- Ingalls Memorial Hospital
-
-
Louisiana
-
Baton Rouge, Louisiana, Verenigde Staten, 70809
- Hematology Oncology Clinic- Baton Rouge/Sarah Cannon Research Institute/SCRI
-
Lake Charles, Louisiana, Verenigde Staten, 70601
- Clinical Trials of SWLA
-
-
Maine
-
Lewiston, Maine, Verenigde Staten, 04240
- Central Maine Medical Center
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21237
- Mfsmc-Hjwci
-
Clinton, Maryland, Verenigde Staten, 20735
- Maryland Oncology Hematology, P.A. - Clinton
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana Farber Cancer Institute
-
Danvers, Massachusetts, Verenigde Staten, 01923
- MGH Northshore Cancer Center
-
Fairhaven, Massachusetts, Verenigde Staten, 02719
- Southcoast Centers for Cancer Care
-
Foxborough, Massachusetts, Verenigde Staten, 02035
- Dana-Farber Cancer Institute - Foxborough
-
Methuen, Massachusetts, Verenigde Staten, 01844
- Dana Farber Cancer Center Merrimack Valley
-
Milford, Massachusetts, Verenigde Staten, 01757
- Dana Farber Cancer Institute
-
Newton, Massachusetts, Verenigde Staten, 02462
- Mass General Cancer Center
-
South Weymouth, Massachusetts, Verenigde Staten, 02190
- Dana Farber Cancer Institute
-
Worcester, Massachusetts, Verenigde Staten, 01606
- Reliant Medical Group
-
-
Montana
-
Billings, Montana, Verenigde Staten, 59102
- St. Vincent Frontier Cancer Center
-
-
New Hampshire
-
Londonderry, New Hampshire, Verenigde Staten, 03053
- Dana Farber Cancer Center Londonderry
-
-
New Mexico
-
Albuquerque, New Mexico, Verenigde Staten, 87106
- University of New Mexico Comprehensive Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02906
- Lifespan Cancer Institute
-
-
Tennessee
-
Chattanooga, Tennessee, Verenigde Staten, 37404
- Tennessee Oncology-Chattanooga /Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Verenigde Staten, 37203
- Sarah Cannon Research Institute/SCRI
-
Nashville, Tennessee, Verenigde Staten, 37203
- Tennessee Oncology-Nashville/Sarah Cannon Research Institute/SCRI
-
-
Texas
-
Bedford, Texas, Verenigde Staten, 76022
- Texas Oncology - Bedford
-
Denton, Texas, Verenigde Staten, 76201
- Texas Oncology - Denton
-
El Paso, Texas, Verenigde Staten, 79902
- Texas Oncology, P.A.
-
Houston, Texas, Verenigde Staten, 77030-4009
- University of Texas MD Anderson Cancer Center
-
McKinney, Texas, Verenigde Staten, 75071
- Texas Oncology - McKinney
-
McKinney, Texas, Verenigde Staten, 75071
- Woodlands Medical Specialists, PA
-
Mesquite, Texas, Verenigde Staten, 75150
- Woodlands Medical Specialists, PA
-
Plano, Texas, Verenigde Staten, 75093
- Texas Oncology-Plano West
-
Plano, Texas, Verenigde Staten, 75075-7787
- Texas Oncology - Plano East
-
San Antonio, Texas, Verenigde Staten, 78229
- Mays Cancer Center
-
The Woodlands, Texas, Verenigde Staten, 77380
- US Oncology
-
Tyler, Texas, Verenigde Staten, 75702
- Texas Oncology - Tyler Cancer Center
-
-
Utah
-
Murray, Utah, Verenigde Staten, 84107
- Intermountain Medical Center
-
St. George, Utah, Verenigde Staten, 84790
- Intermountain Healthcare - St. George
-
-
Vermont
-
Burlington, Vermont, Verenigde Staten, 05401
- The University of Vermont Medical Center Inc.
-
-
Virginia
-
Winchester, Virginia, Verenigde Staten, 22601
- Shenandoah Oncology, P.C.
-
-
-
-
Kyǒnggi-do
-
Seongnam, Kyǒnggi-do, Zuid -Korea, 13620
- Seoul National University Bundang Hospital
-
-
Seoul-teukbyeolsi [Seoul]
-
Seoul, Seoul-teukbyeolsi [Seoul], Zuid -Korea, 02841
- Korea University Anam Hospital
-
Seoul, Seoul-teukbyeolsi [Seoul], Zuid -Korea, 08308
- Korea University Guro Hospital
-
-
Taegu-Kwangyǒkshi
-
Daegu, Taegu-Kwangyǒkshi, Zuid -Korea, 41404
- Kyungpook National University Chilgok Hospital
-
-
-
-
Stockholms
-
Stockholm, Stockholms, Zweden, 171 76
- Karolinska Universitetssjukhuset Solna
-
-
Örebro Län [se-18]
-
Örebro, Örebro Län [se-18], Zweden, 701 85
- Universitetssjukhuset Örebro
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
Have a diagnosis of HR+, HER2- locally advanced or metastatic breast cancer
-
Have radiologic evidence of disease progression or recurrence either
- On treatment with a CDK4/6 inhibitor with aromatase inhibitor (AI) as initial therapy for advanced disease, or
- On/after treatment with a CDK4/6 inhibitor plus endocrine therapy (ET) administered as adjuvant therapy for early stage breast cancer
-
Must be deemed appropriate for treatment with ET
-
If female, have a postmenopausal status by natural or surgical means or by ovarian function suppression
-
Have Response Evaluable Criteria in Solid Tumors (RECIST) evaluable disease (measurable disease and/or nonmeasurable disease)
-
Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale (Oken et al. 1982)
-
Have adequate renal, hematologic, and hepatic organ function
-
Must be able to swallow capsules/tablets
Exclusion Criteria:
- Have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis
- Have symptomatic or untreated central nervous system metastasis
- Have received any systemic therapy between disease recurrence/progression and study screening
- Have received more than 1 line of therapy for advanced or metastatic disease.
- Have received prior chemotherapy for metastatic breast cancer (MBC)
- Have received prior treatment with fulvestrant, any investigational estrogen receptor (ER)-directed therapy (including selective ER degraders [SERDs] and non-SERDs), any phosphatidylinositol 3-kinase (PI3K)-, mammalian target of rapamycin (mTOR)-, or protein kinase B (AKT)-inhibitor
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Dubbele
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A: Abemaciclib plus Fulvestrant
Abemaciclib 150 milligram (mg) administered orally twice daily (BID) on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered intramuscularly (IM) on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered orally. Administered IM. |
|
Actieve vergelijker: Arm B: Placebo plus Fulvestrant
Placebo administered orally BID on Days 1 to 28 of a 28-day cycle in combination with fulvestrant 500 mg administered IM on Days 1 and 15 of Cycle 1, then on Day 1 of Cycle 2 and beyond. Participants received treatment until discontinuation criteria were met. |
Administered IM. Administered orally. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-Free Survival (PFS)
Tijdsspanne: Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
PFS defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 21 Months)
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression Free Survival (PFS) Determined by Blinded Independent Central Review (BICR)
Tijdsspanne: Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
PFS is defined as the time from the date of randomization to the earliest date of disease progression determined by blinded independent central review (BICR) or death from any cause, whichever occurs first. |
Randomization to the date of first documented progression of disease or death from any cause (Up to 22 Months)
|
|
Objective Response Rate (ORR): Percentage of Participants Who Achieved a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)
Tijdsspanne: Randomization until measured progressive disease (Up to 22 Months)
|
ORR is the best overall tumor response of CR or PR as classified by the investigator according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of non-target lesions or appearance of new lesions. |
Randomization until measured progressive disease (Up to 22 Months)
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Publicaties en nuttige links
Algemene publicaties
- Zapatero-Solana E, Ding Y, Pulliam N, de Dios A, Ortiz-Ruiz MJ, Lallena MJ. Models of Early Resistance to CDK4/6 Inhibitors Unveil Potential Therapeutic Treatment Sequencing. Int J Mol Sci. 2025 Mar 14;26(6):2643. doi: 10.3390/ijms26062643.
- Kalinsky K, Bianchini G, Hamilton E, Graff SL, Park KH, Jeselsohn R, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Munoz M, Lai JI, Knoderer H, Sandoval C, Chawla AR, Nguyen B, Zhou Y, Ravenberg E, Litchfield LM, Smyth L, Wander SA. Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial. J Clin Oncol. 2025 Mar 20;43(9):1101-1112. doi: 10.1200/JCO-24-02086. Epub 2024 Dec 18.
- Kalinsky K, Wander SA, Hamilton E, Graff SL, Jeselsohn R, Park KH, Demirci U, Martin M, Layman RM, Hurvitz SA, Sammons S, Kaufman PA, Ravenberg E, Amdur S, Litchfield LM, Bianchini G. Overall survival from the phase III postMONARCH trial of abemaciclib plus fulvestrant versus placebo plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy. Ann Oncol. 2026 Oct 24:S0923-7534(26)08075-0. doi: 10.1016/j.annonc.2026.10.1283. Online ahead of print.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Pathologische processen
- Neoplasmata per site
- Neoplasmata
- Neoplastische processen
- Huidziektes
- Borst ziekten
- Pathologische aandoeningen, tekenen en symptomen
- Huid- en bindweefselaandoeningen
- Borstneoplasmata
- Neoplasma metastase
- Hormonen
- Hormonen, hormoonvervangers en hormoonantagonisten
- Polycyclische verbindingen
- Steroïden
- Verbindingen met gefuseerde ring
- Estradiol
- Woest
- Estranes
- Estradiol -congeners
- Gonadale steroïde hormonen
- Gonadale hormonen
- Fulvestrant
- abemaciclib
Andere studie-ID-nummers
- 18238
- I3Y-MC-JPEF (Andere identificatie: Eli Lilly and Company)
- 2021-002301-10 (EudraCT-nummer)
- 2023-506771-10-00 (Andere identificatie: EU Trial Number)
- 2023 (Subsidie/contract van de Amerikaanse NIH)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
IPD-tijdsbestek voor delen
Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
IPD-toegangscriteria voor delen
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .